48 assets in Uterine Corpus Cancer

Therapeutic assets addressing Uterine Corpus Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Uterine Corpus Cancer	City of Hope Medical Center	P3	BB (66)
Cabozantinib Uterine Corpus Cancer	M.D. Anderson Cancer Center	P2	BB (64)
Irinotecan Uterine Corpus Cancer	M.D. Anderson Cancer Center	P2	BB (64)
Capivasertib Uterine Corpus Cancer	M.D. Anderson Cancer Center	P2	B (60)
Nivolumab Uterine Corpus Cancer	M.D. Anderson Cancer Center	P2	B (60)
Olaparib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	B (60)
Palbociclib Uterine Corpus Cancer	Pamela Munster	P2	B (60)
Sapanisertib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	B (60)
Adavosertib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	B (57)
Dasatinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	B (57)
Binimetinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Cediranib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Crizotinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Dabrafenib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Defactinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Durvalumab Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Fexagratinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Gsk-2636771 Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ipatasertib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Osimertinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pertuzumab Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Relatlimab Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Tazemetostat Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Trametinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Trastuzumab Emtansine Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Vismodegib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Copanlisib Uterine Corpus Cancer	NRG Oncology	P2	CCC (51)
Taselisib Uterine Corpus Cancer	National Cancer Institute (NCI)	P2	CCC (51)
Cyclophosphamide Uterine Corpus Cancer	Mayo Clinic	P1/2	CCC (48)
Pembrolizumab Uterine Corpus Cancer	Mayo Clinic	P1/2	CCC (48)
Sargramostim Uterine Corpus Cancer	Mayo Clinic	P1/2	CCC (48)
Adriamycin Uterine Corpus Cancer	City of Hope Medical Center	P1	CC (43)
Atezolizumab Uterine Corpus Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Ceralasertib Uterine Corpus Cancer	National Cancer Institute (NCI)	P1	CC (43)
Cis-Diamminedichloroplatinum Ii Uterine Corpus Cancer	City of Hope Medical Center	P1	CC (43)
Cobimetinib Uterine Corpus Cancer	National Cancer Institute (NCI)	P1	CC (43)
Fluorouracilum Uterine Corpus Cancer	City of Hope Medical Center	P1	CC (43)
Ipn 60090 Uterine Corpus Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Muamycin Uterine Corpus Cancer	City of Hope Medical Center	P1	CC (43)
Oxaliplatin Uterine Corpus Cancer	City of Hope Medical Center	P1	CC (43)
Pelcitoclax Uterine Corpus Cancer	National Cancer Institute (NCI)	P1	CC (43)
Talazoparib Uterine Corpus Cancer	M.D. Anderson Cancer Center	P1	CC (43)
Trastuzumab Deruxtecan Uterine Corpus Cancer	National Cancer Institute (NCI)	P1	CC (43)
Vistusertib Uterine Corpus Cancer	M.D. Anderson Cancer Center	P1	CC (43)